MedDataX Logo

Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain

NCT ID: NCT01339156

Last Updated: 2012-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

P3914 a pro-drug of Naproxen, characterized by naproxen (COX inhibiting moiety) linked to a NO moiety is intended for the treatment of pain and inflammation. The rationale behind development of P3914 is to maintain the analgesic, antipyretic and anti-inflammatory activity of naproxen and enhance GI safety by virtue of release of NO besides with no major effect on blood pressure on long-term administration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Dental Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Safety Tolerability Food Effect Pharmacokinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

P3914

Group Type EXPERIMENTAL

P3914

Intervention Type DRUG

Part A:

The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.

Part B:

Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).

The investigational product will be administered orally to each subject with 240 mL of water.

Part C:

Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.

For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.

Part D:

Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Part A:

The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.

Part B:

Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).

The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.

Part D:

Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

P3914

Part A:

The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.

Part B:

Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).

The investigational product will be administered orally to each subject with 240 mL of water.

Part C:

Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.

For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.

Part D:

Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Intervention Type DRUG

Placebo

Part A:

The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.

Part B:

Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).

The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.

Part D:

Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* for Part A, Part B and Part C

1. Male subjects aged between 18 and 45 years (including both) with Body Mass Index between 18 to 25 kg/m2 (including both).
2. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
3. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
4. Subjects having clinically acceptable X-Ray chest (P/A view).
5. Subjects having clinically acceptable endoscopy.
6. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
7. Have negative alcohol breath test.
8. Subjects willing to adhere to the protocol requirements and to provide written informed consent.

Part D:

Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on VAS) after removal of an impacted third mandibular molar will be selected for study participation, if they meet the following criteria:

1. Male patients aged between 18 and 60 years (including both).
2. Patients with acute postoperative dental pain (at least moderate in severity or score of 40 mm on Visual Analogue Scale)
3. Patients with otherwise normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable normal range.
4. Patients having clinically acceptable 12-lead electrocardiogram (ECG).
5. Patients having clinically acceptable chest X-Ray (P/A view).
6. Patients having clinically acceptable endoscopy.
7. Have a negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
8. Have negative alcohol breath test.
9. Patients willing to adhere to the protocol requirements and to provide written informed consent.

Exclusion Criteria

* Part A, Part B and Part C:

1. Hypersensitivity to NSAIDs or nitrodonating drugs.
2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within one month of the study starting.
4. History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
5. History of peptic ulceration or significant dyspepsia as judged by the investigator.
6. Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator.
7. Have positive test for Helicobacter pylori infection.
8. Orthostatic hypotension with a systolic blood pressure drop of ≥ 25 mm Hg and/or a diastolic blood pressure drop of ≥ 15 mm Hg within 5 minutes of standing when changing from supine to erect position.
9. A history of renal impairment, or a glomerular filtration rate (GFR) \<60 mL/min or, at visit 1, a serum creatinine value \>140 mol/L.
10. Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit.
11. Subjects currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion).
12. Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal/traditional medicine preparations) during the last one week prior to initiation of study.
13. History or presence of significant alcoholism or drug abuse in the past one year.
14. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
15. History or presence of smoking or use of other tobacco, pan, gutkha products since last six months.
16. History or presence of significant asthma, urticaria or other allergic reactions.
17. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
18. Difficulty in swallowing solids like tablets or capsules.
19. History or presence of cancer.
20. Difficulty with donating blood.
21. Major illness during three months before screening.
22. Participation in a drug research study within past three months.
23. Donation of blood in the past three months before screening.

For Part D:

1. Hypersensitivity to NSAIDs or nitrodonating drugs.
2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
4. History or presence of significant gastric and/or duodenal ulceration including the last three months or gastroduodenal bleeding including the last six months prior to the screening visit.
5. History of peptic ulceration or significant dyspepsia as judged by the investigator.
6. Endoscopy finding of gastric or duodenal ulcer at baseline. Erosive esophagitis or other endoscopic appearance that constitutes a risk to the subject, if included in the study, as judged by the investigator.
7. Have positive test for Helicobacter pylori infection.
8. Orthostatic hypotension with a systolic blood pressure drop of ≥ 25 mm Hg and/or a diastolic blood pressure drop of ≥ 15 mm Hg within 5 minutes of standing when changing from supine to erect position.
9. A history of renal impairment, or a glomerular filtration rate (GFR) \<60 mL/min or, at visit 1, a serum creatinine value \>140 mol/L.
10. Use of aspirin, H2 antagonists, antacids, misoprostol, proton pump inhibitors, sucralfate including two weeks prior to the screening visit.
11. Patients currently taking sildenafil, anticoagulants or ticlopidine, nitrates, nitrovasodilating drugs (e.g. nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, glycerin trinitrate), diuretics (in a dose potentially leading to volume depletion).
12. Use of analgesics in the 48 hrs preceding the day of dental surgery except use of acetaminophen until midnight on the day before surgery.
13. Patients with oral surgery in the 30 days before the pre-study visit.
14. Use of any prescribed medication during last two weeks or OTC medicinal products (including herbal preparations) during the last one week prior to initiation of study.
15. History or presence of significant alcoholism or drug abuse in the past one year.
16. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
17. History or presence of smoking or use of other tobacco, pan, gutkha products since last 06 months.
18. History or presence of significant asthma, urticaria or other allergic reactions.
19. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumour.
20. Difficulty in swallowing solids like tablets or capsules.
21. History or presence of cancer.
22. Difficulty with donating blood.
23. Major illness during three months before screening.
24. Participation in a drug research study within past three months.
25. Donation of blood in the past three months before screening.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Piramal Enterprises Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Dharmesh Domadia

Role: PRINCIPAL_INVESTIGATOR

Veeda Clinical research private limited

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P3914/48/10

Identifier Type: -

Identifier Source: org_study_id